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Rejuvenation of the term Sarcopenia 46 
It is our viewpoint that the recent consensus definitions of Sarcopenia are dysfunctional for clinical and 47 
experimental practice as well as in theory. In 1989 the term Sarcopenia was introduced to describe the 48 
phenomenon of age related loss of lean body mass(10). Since 2010 six consensus definitions have been 49 
presented, and in 2016 it was assigned its own ICD-10 code(1, 3, 5, 6, 8, 9, 11).  A comparison of the 50 
original definition with the new consensus definitions clarifies how the term Sarcopenia no longer describes 51 
the phenomenon it originally addressed. Rather, the term is now caught in tautological association, which 52 
causes confusion and hinders rather than helps understanding of this condition.   53 
The original definition 54 
In 1989, Rosenberg observed that the phenomenon of decreasing lean body mass with older age had not been 55 
given the scientific attention it deserved, and drew attention to it, in suggesting a name combining the two 56 
words sarco (meaning flesh) and penia (meaning loss), in accordance with the characteristic that it 57 
described(10).  The focus of this original definition was the loss of muscle mass as a discrete phenomenon, 58 
with a leading interest in legitimizing clinical and scientific attention to it(10). This definition of Sarcopenia 59 
was used descriptively with the purpose of defining and articulating the loss of skeletal muscle mass, as a 60 
concrete object. 61 
The new consensus definitions 62 
Between 2011 and 2014, six consensus definitions of Sarcopenia were agreed (3, 5, 6, 8, 9, 11). These 63 
shifted the focus from the original phenomenon of loss of skeletal muscle mass to that of physical function. 64 
All of these definitions employ an algorithm with the same logic. Physical function capability is initially 65 
assessed (gait speed or grip strength), and only if function is impaired below a cut-point, is muscle mass (as 66 
the appendicular lean mass (ALM)) secondarily evaluated. Hence, low muscle mass is not a single stand-67 
alone determinant by which Sarcopenia is defined, and having only a low muscle mass is not an adequate 68 
criterion by which to be defined as being Sarcopenic. Physical function is not synonymous with muscle 69 
function although the concepts are sometimes used interchangeable in the six consensus articles. Physical 70 
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function is an interplay between multiple organ systems that can be estimated through tests like gaitspeed 71 
whereas skeletal muscle, besides having the capability of contracting and allowing movement, has many 72 
functions in metabolism and as an endocrine organ.  73 
The consensus definitions were made by working groups, with representatives from different Societies 74 
within the geriatric field, in Europe, the United States and Asia, two of them receiving partial funding from 75 
the pharmaceutical industry. Discussion surrounding these definitions focusses most strongly on 76 
determination of the exact cut-off values for both physical function tests and muscle mass measurements. 77 
Surprisingly, the theoretical framework underpinning the definitions is not discussed thoroughly in any of the 78 
articles and  arguments for the inclusion of physical function is found in only three(5, 8, 11) of the six 79 
papers.  They share one main argument only, that the original definition is not clinically relevant.  80 
 81 
Questioning the reasoning for changing the definition 82 
The main argument for including physical function in the definition is at least two-fold. Firstly, if a well-83 
defined phenomenon is not clinically relevant, changing the definition does not make it become clinically 84 
relevant. Instead, it changes the phenomenon under consideration. Secondly, every definition can become 85 
clinically relevant by adding a criterion that is clinically relevant, as in this case with physical function. The 86 
linking of loss of skeletal muscle mass to physical function reflects the logic behind the change of focus in 87 
the research field of sarcopenia, which is notably absent from the consensus articles. During the 1990s there 88 
was a research drive to develop operational criteria for cutoff values for categorizing adults as suffering from 89 
Sarcopenia.  The initial suggestion for an operational criterion and cutoff value was established by 90 
Baumgartner in 1998, who legitimized the criterion by showing its association with a decrease in physical 91 
function and mortality(2). This initiated the shift in focus from muscle mass to physical function. From 92 
around 2000, the research focus shifted to considerations of how muscle strength and physical function such 93 
as gait speed have stronger association than low muscle mass to a decrease in physical function and 94 
mortality. Instead of concentrating on the loss of muscle mass, research interest centered on the robustness of 95 
the phenomenon’s association with decreased physical function and mortality, thereby making physical 96 
function the primary object of interest.  97 
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From a clinical perspective it appears reasonable to focus on the phenomenon with the strongest association 99 
to a negative health outcome. However, in this case the outcome and the phenomenon is almost, if not 100 
exactly, identical, and the argument for the change of focus from muscle mass to physical function is a 101 
tautology – arguing that there should be a change in focus from decreased muscle mass to decreased physical 102 
function, since a decrease in physical function has a stronger association with a decrease in physical 103 
function. 104 
 105 
There are several consequences of the change in definition. According to the algorithms used in the 106 
consensus definitions, skeletal muscle is only of value to the definitions if it is associated with bodily 107 
movement. If gait speed is not reduced, presence of a low muscle mass is irrelevant according to the 108 
consensus definitions. This is despite the fact that skeletal muscle is the largest metabolic organ of the body, 109 
and is crucial in the endocrine regulation of metabolism as well as being the body’s largest reservoir of 110 
amino acids(7). Such functions are likely to be overlooked clinically when the primary inclusion criterion for 111 
sarcopenia is physical function and not muscle mass. Likewise, physical function is at risk of being reduced 112 
to the question of muscle mass when both are directly coupled in the definition(4). Further, it reduces the 113 
relevance of the term in other clinical specialties such as nephrology and endocrinology, where muscle mass 114 
per se could be of clinical importance for both categorizing patients as well as in selecting treatment. Beside 115 
the reductionist understanding of the two different phenomena, the new definitions also lead to general 116 
confusion of what is meant by the term Sarcopenia, since it no longer covers one but two phenomena.  117 
 118 
Conclusion 119 
Since the reasoning behind the change in definition of sarcopenia rests upon a tautological association, and 120 
that the meaning of the term has become misleading as it no longer corresponds with the phenomenon that it 121 
addresses, we suggest a return to the use of the original definition for future research.  ‘Sarcopenia’ should 122 
exclusively be used as a descriptive term addressing age-related loss of muscle mass. This would return 123 
focus onto uncovering the causes and consequences of the phenomenon, and clinicians will hereby have an 124 
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unambiguous and useful term. Perhaps returning to the original definition could cause confusion in relation 125 
to acceptance of age related loss of muscle mass as a clinical relevant phenomenon. However, the theoretical 126 
foundations of the consensus definitions are tautological, and we anticipate that the consequences of these 127 
definitions would continue to create confusion. There may be other and better definitions than the original 128 
but since nobody will benefit from the current consensus definitions, breaking out of the tautology is 129 
necessary to allow science and clinical practice to move on.  130 
  131 
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